CONSTITUENT REPORT
Fenchone
Fenchone is a bicyclic monoterpene ketone best known as a fennel- and cedarleaf-associated aroma constituent with a camphoraceous profile. The live evidence base is moderate by archive standards: identity and flavor-safety references are solid, and several recent animal or in vitro papers report antimicrobial, anti-inflammatory, diuretic, gastrointestinal-motility, and macrophage-signaling effects. Those findings are still preclinical, so the record should frame fenchone as a chemistry-rich, pharmacology-emerging constituent rather than an established medical active.
Chemical identity and composition
PubChem records fenchone as CID 14525 with formula C10H16O and IUPAC name 1,3,3-trimethylbicyclo[2.2.1]heptan-2-one. The public JECFA flavor specifications separate enantiomers, with l-fenchone listed as alpha-fenchone and d-fenchone listed as an acceptable flavoring agent at current intake levels; the archive record here treats 'fenchone' as the common constituent umbrella used in oil GC profiles. In the local archive, fenchone is a major secondary marker in bitter fennel and cedar leaf thuja and a smaller supporting marker in sweet fennel and Seville lavender profiles.
Aroma and practical use
- Use the recorded camphoraceous, herbal, earthy, woody, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2022 Plants study found that fenchone reduced biofilm production in E. coli, P. aeruginosa, and C. albicans by about 70.03%, 64.72%, and 61.71% at 1 mg/mL in the reported in vitro assay, with measurable antibacterial and antifungal activity.
A 2022 Plants study found that fenchone reduced biofilm production in E. coli, P. aeruginosa, and C. albicans by about 70.03%, 64.72%, and 61.71% at 1 mg/mL in the reported in vitro assay, with measurable antibacterial and antifungal activity.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2023 Frontiers in Pharmacology rat study reported that oral fenchone at 400 mg/kg increased urine output and electrolyte excretion in saline-loaded rats after an OECD-guided acute-toxicity assessment.
A 2023 Frontiers in Pharmacology rat study reported that oral fenchone at 400 mg/kg increased urine output and electrolyte excretion in saline-loaded rats after an OECD-guided acute-toxicity assessment.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2023 Inflammopharmacology rat study reported that fenchone reduced CFA-model inflammatory markers including iNOS, IL-17, IL-1beta, IL-6, TNF-alpha, COX-2, NO, and PGE2, supporting anti-inflammatory activity in that model.
A 2023 Inflammopharmacology rat study reported that fenchone reduced CFA-model inflammatory markers including iNOS, IL-17, IL-1beta, IL-6, TNF-alpha, COX-2, NO, and PGE2, supporting anti-inflammatory activity in that model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2024 Journal of Microbiology and Biotechnology study reported that fenchone improved stool parameters, intestinal transit, visceral hypersensitivity, SCF/c-Kit expression, and several gut-microbiota shifts in a rat IBS-C model.
A 2024 Journal of Microbiology and Biotechnology study reported that fenchone improved stool parameters, intestinal transit, visceral hypersensitivity, SCF/c-Kit expression, and several gut-microbiota shifts in a rat IBS-C model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2025 macrophage-model study reported that fenchone reduced 7-ketocholesterol-driven lipid accumulation and inflammatory signaling while shifting markers toward M2 polarization in murine IC-21 macrophages.
A 2025 macrophage-model study reported that fenchone reduced 7-ketocholesterol-driven lipid accumulation and inflammatory signaling while shifting markers toward M2 polarization in murine IC-21 macrophages.
This experimental finding does not establish benefit, dose or safety in people using this blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedJECFA's d-fenchone evaluation states there is no safety concern at current levels of intake when used as a flavouring agent, and FAO's later l-fenchone specification page lists a full specification with a camphor-herbal-earthy-woody aroma description.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
The recent diuretic study used OECD guideline 425 for acute oral toxicity work in rats and described the tested acute dose as tolerated in that model, but this is not a substitute for human safety data.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
No controlled human clinical efficacy or dedicated dermal-sensitization dataset for isolated archive-level fenchone was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
trans-AnetholeAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
review · whole_oil
No source citation attached.
Read trans-Anethole report →How the effects were investigated
biofilm reduction and antifungal activity
In vitro studies report that fenchone reduces biofilm production in tested bacterial and Candida models and shows fungicidal activity against fungal strains in the cited assays.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
pro inflammatory pathway modulation
Rat and macrophage-model studies report that fenchone lowers inflammatory markers including iNOS, PGE2, NF-kB-linked cytokines, and several M1-associated signatures while increasing anti-inflammatory signals in those models.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
gut motility and neurotransmitter modulation
Rodent gastrointestinal studies describe antimotility effects in diarrhea models and improved transit plus neurotransmitter and SCF/c-Kit changes in IBS-C models, indicating context-dependent gut pathway modulation rather than a single simple action.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- The archive-level fenchone record aggregates literature across racemic and enantiomer-specific naming because oil GC profiles usually report 'fenchone' generically.
- Current activity literature is overwhelmingly preclinical and should not be translated into medical claims.
- A stronger constituent-specific human safety or dermal-sensitization evidence base was not verified in this pass.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.